Cellscape has named Ted Snelgrove as its new CEO.
Snelgrove joins the prenatal genetic testing firm from Crescendo Bioscience, where he served as chief commercial officer. He also worked previously at Genomic Health, where he was vice president of sales and marketing.
Bernard Sixt has joined ImmunID as its new president and CEO.
Sixt was CEO of Agendia from 2003 to 201. He takes over the CEO position from ImmunID cofounder Nicolas Pasqual, who will continue on as the company's chief scientific officer.
Cancer Genetics has named Keith Brownlie to its board of directors and to its audit committee. Brownlie has served as the audit partner for a number of life sciences companies, including Epicet and Rxi Pharmaceuticals.